Patent intelligence · US
US 9771366
Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors
Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors
Patent details — US 9771366
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 26, 2017
- Expiration
- Sep 21, 2037
- Applicant
- PHOENIX MOLECULAR DESIGNS
- Claims
- 20
- CPC classes
- A61K, A61K31/337, A61K31/4355, A61K31/437
Quick answer
US 9771366 (Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors) is held by PHOENIX MOLECULAR DESIGNS. Status: granted. Granted Sep 26, 2017. Expires Sep 21, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PHOENIX MOLECULAR DESIGNS
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/337, A61K31/4355, A61K31/437, A61K31/496, A61K31/4985
More from PHOENIX MOLECULAR DESIGNS
Related pharmaceutical patents in our USPTO index.
-
US 12378245
Crystalline forms of an RSK inhibitor
granted -
US 12297243
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
granted -
US 12291058
Dispersions for additive manufacturing comprising discrete carbon nanotubes
granted -
US 12268695
Betulin-containing birch bark extracts and their formulation
granted -
US 12247004
2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use
granted -
US 12065498
Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same
granted -
US 12005194
Configurable oxygen concentrator and related method
granted -
US 11998571
Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease
granted
Frequently asked questions
What is US patent 9771366?
US 9771366 (Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors) is held by PHOENIX MOLECULAR DESIGNS. Status: granted. Granted Sep 26, 2017. Expires Sep 21, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9771366?
PHOENIX MOLECULAR DESIGNS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 201 pharmaceutical patents for this assignee.
When does US 9771366 expire?
Our index shows an expiration date of Sep 21, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.